Carl D. Schlenkhoff
Bonn, NW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Lutetium-177-PSMA radioligand therapy : Consensus within the framework of GKV-funded care between the university hospitals in Aachen, Bonn, Düsseldorf, Essen, and Cologne and the MDK Nordrhein
Journal: Der Urologe. Ausg. A
Published: April 20, 2018
Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy.
Journal: Oncotarget
Published: August 25, 2017
Combination of 177Lu-PSMA-617 and External Radiotherapy for the Treatment of Cerebral Metastases in Patients With Castration-Resistant Metastatic Prostate Cancer.
Journal: Clinical nuclear medicine
Published: July 19, 2017
Possible Treatment Approach to an Extravasation of 177Lu-PSMA-617.
Journal: Clinical nuclear medicine
Published: June 03, 2017
[18F]Fluorodeoxyglucose Positron Emission Tomography Reveals a Complete Remission of Refractory Metastatic Melanoma after Therapy with Ipilimumab.
Journal: Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India
Published: March 01, 2017
Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617.
Journal: European journal of nuclear medicine and molecular imaging
Published: February 13, 2017
Successful Treatment of Hepatic Metastases of Hormone Refractory Prostate Cancer Using Radioligand Therapy With 177Lu-PSMA-617.
Journal: Clinical nuclear medicine
Published: September 09, 2016
68Ga-PSMA-11 PET Represents the Tumoricidal Effect of 223Ra in a Patient With Castrate-Resistant Metastatic Prostate Cancer.
Journal: Clinical nuclear medicine
Published: July 13, 2016
Positive Influence of 177Lu PSMA-617 Therapy on Bone Marrow Depression Caused by Metastatic Prostate Cancer.
Journal: Clinical nuclear medicine
Published: February 25, 2016
Metastatic Prostate Cancer With Restored Hormone-Response After Radioligand Therapy With 177Lu-PSMA-617.
Journal: Clinical nuclear medicine
Published: February 25, 2016
68Ga-Labeled Anti-Prostate-Specific Membrane Antigen Peptide as Marker for Androgen Deprivation Therapy Response in Prostate Cancer.
Journal: Clinical nuclear medicine
Published: February 10, 2016
Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer.
Journal: Oncotarget
Published: October 26, 2015
Last Updated: 09/26/2026